JNJ Stock Recent News

For retirees seeking income, dividend investing is less about chasing the highest yield and more about owning stocks that reliably generate cash and consistently increase their payouts. Add in stability, safety, and diversification across industries and you have the hallmarks of an ideal retirement dividend portfolio.

Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration.

J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.

Johnson & Johnson on Thursday committed to invest $2 billion in North Carolina to expand the drugmaker's U.S. manufacturing presence.

For long-term investors, dividend-paying companies remain a key factor as they provide both income and stability.

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share.

You can't time the market, but you can bank on a good dividend. Especially when stocks are swinging in volatile times, reliable income is a rare anchor.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.